Publisher
Springer Berlin Heidelberg
Reference52 articles.
1. Al-Shahwan S, Al-Torbak AA, Turkmani S, Al-Omran M, Al-Jadaan I, Edward DP (2005) Side-effect profile of brimonidine tartrate in children. Ophthalmology 112(12):2143. https://doi.org/10.1016/j.ophtha.2005.06.035
2. Aroney C, Fraser-Bell S, Lamoureux EL, Gillies MC, Lim LL, Fenwick EK (2016) Vision-related quality of life outcomes in the BEVORDEX study: a clinical trial comparing ozurdex sustained release dexamethasone intravitreal implant and Bevacizumab treatment for diabetic macular edema. Invest Ophthalmol Vis Sci 57(13):5541–5546. https://doi.org/10.1167/iovs.16-19729
3. Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR, Oellers PR, Leveque TK, Rutledge BK, Chittum M, Bacci T, Enriquez AB, Sund NJ, Subong ENP, Albini TA (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 127(10):1345–1359. https://doi.org/10.1016/j.ophtha.2020.04.017
4. Behrens-Baumann W, Begall T (1993) Antiseptics versus antibiotics in the treatment of the experimental conjunctivitis caused by Staphylococcus aureus. Ger J Ophthalmol 2(6):409–411 (https://www.ncbi.nlm.nih.gov/pubmed/8312825)
5. Ben-Eli H, Solomon A (2018) Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Curr Opin Allergy Clin Immunol 18(5):411–416. https://doi.org/10.1097/ACI.0000000000000473